

Publikationen (seit 2000)

1. Binder R., Kress, A., Kan, G., Hermann, K., **Kirschfink, M.** Neutrophil priming by cytokines and vitamin D binding protein (Gc-globulin): Impact on C5a-mediated chemotaxis, degranulation and respiratory burst. *Mol Immunol* 2000; 36: 885-892.
2. Heller, A., Koch T., **Kirschfink, M.** Impact of C1-INH and sCR-1 on respiratory failure after complement activation. In: 5th World Congress on Trauma, Shock, Inflammation Sepsis (ed. E. Faist). Mundozzi Editore Bologna 2000: 161-165.
3. Jurianz K., **Kirschfink M.** Therapeutic complement inhibition. In: Faist, Baue (eds) Immune consequences of trauma shock and sepsis. Springer Verlag, Heidelberg, New York 2000, Chapter 23, pp 214-223.
4. T.G. Lehmann, M. Heger, S. Muench, **M. Kirschfink**, E. Klar. In vivo microscopy reveals that complement inhibition by C1-esterase inhibitor reduces ischemia/reperfusion injury in the liver. *Transplant Int* 2000; 13 [Suppl 1]: S547-S550.
5. Radke, A., Mottaghy, K., Goldmann, Ch., Khorram-Sefat, R., Kovacs, B., Janssen, A., Klosterhalfen, B., Hafemann, B., Pallua, N., **Kirschfink, M.** C1-Inhibitor prevents capillary leakage after thermal trauma. *Crit Care Med* 2000; 28:3224-3232.
6. Heller A, Kunz M, Samakas A, Haase M, **Kirschfink M**, Koch T. Complement regulators C1 inhibitor and soluble complement receptor 1 attenuate acute lung injury in rabbits. *Shock* 2000; 13: 285-290.
7. Keldenich S, Kopp R, **Kirschfink M**, Klein B, Heseler A, Thelen H, Oedekoven B, Mottaghy K. Application of a new dynamic flow model for investigating the biocompatibility of modified surfaces. *ASAIO Journal* 2000; 46:134-141.
8. Klima U, Kutschka I, Warnecke G, Kim P, Strüber M, **Kirschfink M**, Haverich A. Improved right ventricular function after intracoronary administration of a C1 esterase inhibitor in a right heart transplantation model. *Eur J Cardio-Thoracic Surgery* 2000; 18:321-327.
9. T. Frietsch, H. Fessler, **M. Kirschfink**, T. Nebe, K. F. Waschke, A. Lorentz. Immune response to autologous transfusion in healthy volunteers - whole blood vs packed red cells and fresh frozen plasma. *Transfusion* 2001; 41:470-476
10. Tolksdorf B, Frietsch T, Quintel M, **Kirschfink M**, Becker P, Lorentz A. Humoral immune response to autologous blood transfusion in hip surgery: whole blood versus packed red cells and plasma. *Vox Sang* 2001; 81:180-186.
11. Schwertz R, Rother U, Anders D, Gretz N, Schärer K, **Kirschfink M.** Complement analysis in children with idiopathic membranoproliferative glomerulonephritis: a long-term follow-up. *Pediatric Allergy and Immunology* 2001; 10: 1-8.

12. Kraiczy P, Skerka C, **Kirschfink M**, Zipfel P, Brade V. Mechanism of complement resistance of pathogenic *Borrelia burgdorferi* isolates. *International Immunopharmacology* Vol. 1: 393 - 392, 2001.
13. **Kirschfink M**. Targeting complement in therapy. *Immunol Rev* 2001, 180:177-189.
14. Kirschfink M, Mollnes TE. C1-inhibitor: an antiinflammatory reagent with therapeutic potential. *Exper Opin Pharmacother* 2001;2:1073-1083.
15. Kurjane N, Bruvere R, Shitova O, Romanova T, Jaunalksne I, Kirschfink M, Sochnevs A. Analysis of the immune status in Latvian Chernobyl clean-up workers with nononcological thyroid diseases. *Scand J Immunol* 2001; 54:528-533.
16. Jurianz K, Ziegler S, Donin N, Reiter Y, Fishelson Z, **Kirschfink M**. K562 erythroleukemic cells are equipped with multiple mechanisms of resistance to lysis by complement. *Int J Cancer* 2001; 93:848-854.
17. Kraiczy P, Skerka C, **Kirschfink M**, Brade V, Zipfel P. Immune evasion of *Borrelia burgdorferi* by acquisition of human complement regulators FHL-1/reconectin and factor H. *Eur J Immunol* 2001; 31:1674-1684.
18. Lehmann TG, Koeppl TA, Munch S, Heger M, **Kirschfink M**, Klar E, Post S. Impact of Inhibition of Complement by sCR1 on Hepatic Microcirculation after Warm Ischemia. *Microvasc Res* 2001; 62(3):284-292.
19. Baghat M, Doenhoff M, **Kirschfink M**, Ruppel A. Serine protease and phenoloxidase activities in hemocytes of *Biomphalaria glabrata* with varying susceptibility to infection with the parasite *Schistosoma mansoni*. *Parasitol Res* 2002; 88:489-494.
20. Kraiczy P, Skerka C, **Kirschfink M**, Zipfel P, Brade V. Immune evasion of *Borrelia burgdorferi*: Insufficient killing of the pathogens by complement and antibody. *Int J Med Microbiol* 2002; 291 Suppl 33:141-161.
21. De Moraes Lui C, Oliviera LC, Diogo CL, **Kirschfink M**, Grumach AS. Immunoglobulin G subclass concentrations and infections in children and adolescents with severe asthma. *Pediatr Allergy Immunol* 2002; 13:195-202.
22. Messias-Reason IJ, Hayashi SY, Nisihara RM, **Kirschfink M**. Complement activation in infective endocarditis. Correlation with extracardiac manifestations and prognosis. *Clin Exp Immunol* 2002; 127: 310-315.
23. Messias-Reason IJ, Nisihara RM, Chiu YY, **Kirschfink M**, Radominski SC. Complement activation products as sensitive markers of systemic lupus erythematosus activity. *Rev Bras Rheumatol* 2002; 42:154-159.
24. Böttiger BW, Motsch J, Kern S, Braun V, Bach A, Böhrer H, Martin E, **Kirschfink M**. Marked activation of complement and leukocytes, and increase in the concentrations of soluble endothelial adhesion molecules during early reperfusion following cardiac arrest in humans. *Crit Care Med* 2002; 30:2473-2480.

25. Kopp R, Mottaghy K, **Kirschfink M**. Mechanism of complement activation during extracorporeal blood-biomaterial-interaction: Effects of heparin coated and uncoated surfaces. *ASAIO J* 2002; 48:598-605.
26. **Kirschfink M**. C1-inhibitor and transplantation., *Immunobiol* 2002; 205:534-541.
27. Walker UA, **Kirschfink M**, Peter HH. Improvement of acquired lipodystrophy with rosiglitazone despite ongoing complement activation. *Rheumatology* 2003; 42:393-394.
28. Donin N, Jurianz K, **Kirschfink M**, Fishelson Z. Overcoming complement resistance of carcinoma cells: membrane regulatory proteins, protein phosphorylation and sialic acid. *Clin Exp Immunol* 2003;131: 254-263.
29. Kraiczy P, Hellwage J, Skerka C, **Kirschfink M**, Brade V, Zipfel P, Wallich R. Immune evasion of *Borrelia burgdorferi*: mapping of a complement inhibitor factor H-binding site of BbCRASP-3, a novel member of the Erp protein family. *Eur J Immunol* 2003;33: 697-707.
30. Schulze-Bergkamen. H, Untergasser A, Dax A, Vogel H, Büchler P, Klar E, Lehnert T, Friess H, Büchler MW, **Kirschfink M**, Stremmel W, Krammer P, Müller M, Protzer U. Primary human hepatocytes – a valuable tool for investigation of apoptosis and hepatitis B virus infection. *J Hepatol* 2003; 38:736-744.
31. Steiner T, Jünger J, Schmidt J, Bardenheuer H, **Kirschfink M**, Kadmon M, Schneider G, Seller H, SonntagHG. HEICUMED: Heidelberger Curriculum Medicinale – Ein modularer Reformstudiengang zur Umsetzung der neue Approbationsordnung. *Med. Ausbildung* 2003; 20:87-91.
32. Wosnik A, **Kirschfink M**. Blockade des Komplementsystems bei Xenotransplantation. In: GrimmH (ed.) *Xenotransplantation*. Schattauer, Stuttgart, New York, 2003, pp 103 ff.
33. **Kirschfink M** and Mollnes TE. Modern complement analysis. *Clin Diagn Lab Immunol* 2003; 10: 982-989.
34. Fishelson Z, Donin N, Zell S, Schultz S, and **Kirschfink M**. Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. *Mol Immunol*. 2003;40:109-123.
35. Gerber A, Kirchhoff-Moradpour AH, Obieglo S, Brandis M, **Kirschfink M**, Zipfel PF, Goodship JA, Zimmerhackl LB. Successful (?) therapy of hemolytic-uremic syndrome with factor H abnormality. *Pediatr Nephrol*. 2003;18(9):952-955.
36. Kraiczy P, Hartmann K, Hellwage J, Skerka C, **Kirschfink M**, Brade V, Zipfel P, Wallich R., Stevenson B. Immunological characterization of the complement regulator factor H-binding CRASP and Erp proteins of *Borrelia burgdorferi*. *Int J Med Microbiol* 2004; 293 (Suppl 37): 152-157.
37. Karpel-Massler G, Fleming SD, **Kirschfink M**, Tsokos GC. Human C1 esterase inhibitor attenuates murine mesenteric ischemia/reperfusion induced local organ injury. *J Surg Res* 2003; 115:47-256.

38. Kraiczy P, Hellwage J, Skerka C, Becker H, **Kirschfink M**, Simon M, Brade V, Zipfel P, Wallich R. Complement resistance of *Borrelia burgdorferi* correlates with the expression of BbCRASP-1, a novel linear plasmid-encoded surface protein that interacts with human factor H and FHL-1 and is unrelated to Erp proteins. *J Biol Chem* 2004; 279:2421-242.
39. Crohner RS, Lehmann TG, Fallsehr C, Hefarth C, Klar E, **Kirschfink M**. C1-Inhibitor reduces hepatic leukocyte-endothelial interactions and the expression of VCAM-1 in LPS-induced sepsis in rats. *Microvasc Res* 2004; 67:182-191
40. **Kirschfink M**, Fishelson Z. Tumor cell resistance to complement-mediated lysis. In: Szebeni J (ed.). *The Complement System: Novel roles in health and disease*. Kluwer Academic Publ. 2004, pp 265-304.
41. **Kirschfink M**, Mollnes TE. The role of complement in transplantation. In: Szebeni J (ed.). *The Complement System: Novel roles in health and disease*. Kluwer Academic Publ. 2004, pp 397-418
42. Cordes FS, Kraicy P, Roversi P, Skerka C, **Kirschfink M**, Simon MM, Brade V, Lowe ED, Zipfel P, Wallich R, Lea SM. Crystallization and preliminary crystallographic analysis of BbCRASP-1, a complement regulator-acquiring surface protein of *Borrelia burgdorferi*. *Acta Cryst.* 2004; D60:929-932.
43. Chagas K de N, Arruk VG, Andrade MEBB, Vasconceles DdM, **Kirschfink M**, da Silva Duarte A, Grumach AS. Angioedema Hereditario: Consideracoes sobre terapia. *Rev Assoc Med Bras* 2004; 50:314-319.
44. Lian YC, Della Negra M, Rutz R, Feriani V, de Moraes Vasconcelos, Duarte AjdS, **Kirschfink M**, Grumach AS. Immunological analysis in pediatric HIV patients at different stages of disease. *Scand J Immunol.* 2004;60(6):615-624.
45. Licht C, Weyersberg A, Heinen S, Stapenhorst L, Jacqueline Devenge J, Beck B, Waldherr R, **Kirschfink M**, Zipfel PF, Hoppe B. Successful Plasma Therapy for Atypical Hemolytic Uremic Syndrome (aHUS) caused by Factor H Deficiency due to a Mutation in the Complement Cofactor Protein (CCP) Domain 15. *Am J Kidney Dis.* 2005;45(2), 415-421.
46. Pfarr N, Prawitt D, **Kirschfink M**, Schroff C, Knuf M, Habermehl P, Mannhardt W, Zepp F, Fairbrother W, Loos M, Burge CB, Pohlenz J. Linking C5 deficiency to an exonic splicing enhancer mutation. *J Immunol.* 2005;174(7):4172-4177.
47. Appel GB, Cook HT, Hageman G, Jennette JC, Kashgarian M, **Kirschfink M**, Lambris JD, Lanning L, Lutz HU, Meri S, Rose NR, Salant DJ, Sethi S, Smith RJ, Smoyer W, Tully HF, Tully SP, Walker P, Welsh M, Wurzner R, Zipfel PF. Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. *J Am Soc Nephrol.* 2005 May;16(5):1392-1403.
48. Liberatore Jr RdR, Barbosa SF, Alkimin MdG, Bellinati-PiresR, Florido MPC, IsaaL, **Kirschfink M**, Grumac AS. Is immunity in diabetic patients influencing the susceptibility to infections?. *Pediatric Diabetes* 2005;6:206-212.

49. Haltern C, **Kirschfink M**, Rossaint R, Unger JK. Impact of inverse plasma filtration on complement activation in porcine blood. *Artif Organs*. 2005;29(4):306-312.
50. Schuerholz T, Leuwer M, Cobas-Meyer M, Vangerow B, Kube F, **Kirschfink M**, Marx G, Terminal complement complex in septic shock with capillary leakage: marker of complement activation. *Eur J Anaesthesiol*. 2005 Jul;22(7):541-547.
51. Liberatore Del Rio R Jr, Barbosa SFC, Alkimim M das Gracas, Bellinati-Pires M, Lourdes I, **Kirschfink M**, Grumach AS. Is immunity in diabetic patients influencing the susceptibility to infections? Immunoglobulins, complement and phagocytic function in children and adolescents with type 1 diabetes mellitus. *Pediatric Diabetes* 2005; 6:206-212.
52. Mollnes TE, **Kirschfink M**. Strategies of therapeutic complement inhibition. *Mol Immunol*. 2006 Jan;43(1-2):107-21.
53. Grumach AS, Leitão MF, Arruk VG, **Kirschfink M**, Condino-Neto A. Recurrent infections in partial complement factor I deficiency: evaluation of three generations of a Brazilian family. *Clin Exp Immunol*. 2006;143(2):297-304.
54. Licht C, Heinen S, Józsi M, Löschmann I, Saunders RE, Perkins SJ, Waldherr R, Skerka C, **Kirschfink M**, Hoppe B, Zipfel PF. Deletion of Lys224 in regulatory domain 4 of Factor H reveals a novel pathomechanism for dense deposit disease (MPGNII). *Kidney Int* 2006; 70:42-50.
55. Wang W, **Kirschfink M**, Ruppel A. *Schistosoma japonicum* and *S.mansoni* cercariae: different effects of protein in medium, of mechanical stress and of an intact complement system on in vitro transformation to schistosomula. *Parasitol Res* 2006; 99: 269-274.
56. Sachse MM, Khachemoune A, Guldbakke KK, **Kirschfink M**. Hereditary angioedema. *J Drugs Dermatol*. 2006;5(9):848-852.
57. Hartwig W, Klafs M, **Kirschfink M**, Hackert T, Schneider L, Gebhard MM, Büchler MW, Werner J. Interaction of complement and leukocytes in severe acute pancreatitis: potential for therapeutic intervention. *Am J Physiol Gastrointest Liver Physiol*. 2006;291(5):G844-850
58. Mollnes TE, **Kirschfink M**. Complement analysis in clinic and research. *Adv Exp Med Biol*. 2006;586:361-80.
59. Sachse MM Khachemoune A, Guldbakke KK, **Kirschfink M**. Hereditary Angioedema. *J Drugs Dermatol* 2006; 5; 717-721.
60. Hartmann K, Corvey C, Skerka C, **Kirschfink M**, Karas M, Brade V, Miller JC, Stevenson B, Wallich R, Zipfel PF, Kraiczy P. Functional characterization of BbCRASP-2, a distinct outer membrane protein of *Borrelia burgdorferi* that binds host complement regulator factor H and FHL-1. *Mol. Microbiol* 2006; 61:1220-1236.
61. Konatschnig T, Geis N, Schultz S, **Kirschfink M** . Complement resistance impairs anti-tumour therapy. *Radiol Oncol*. 2006;40:95-105.

62. Schwartz-Albiez R, Adams Y, von der Lieth W, Mischnick P, Andrews KT, **Kirschfink M**. Regioselectively modified sulfated cellulose as prospective drug for treatment of malaria tropica. *Glyconjugate J*. 2007; 24:57-65.
63. Licht C, Schlötzer-Schrehardt U, **Kirschfink M**, Zipfel PF, Hoppe B. MPGN II--genetically determined by defective complement regulation? *Pediatr Nephrol*. 2007;22(1):2-9.
64. Rossmann E, Kraiczy P, Herzberger P, Skerka C, **Kirschfink M**, Simon MM, Zipfel PF, Wallich W. Dual binding specificity of a *Borrelia hermsii*-associated complement regulator-acquiring surface protein for Factor H and plasminogen discloses a putative virulence factor of relapsing fever spirochetes *J Immunol* 2007;178:7292-7301.
65. Mollnes TE, Jokiranta TS, Truedsson L, Nilsson B, Rodriguez de Cordoba S, **Kirschfink M**. Complement analysis in the 21th century. *Mol Immunol*, 2007;44:3838-3849.
66. Zell S, Geis N, Rutz R, Schultz S, Giese T, **Kirschfink M**. Down-regulation of CD55 and CD46 expression by anti-sense phosphorothioate oligonucleotides (S-ODNs) sensitizes tumour cells to complement attack. *Clin Exp Immunol* 2007; 150:576-586.
67. Teschendorf P, Albertsmeier M, Vogel P, Padosch SA, Spöhr F, **Kirschfink M**, Schwaninger M, Böttiger BW, Popp E.. Neurological outcome and inflammation after cardiac arrest-Effects of protein C in rats. *Resuscitation*. 2008;79(2):316-324.
68. Schwartz-Albiez R, Laban S, Eichmüller S, **Kirschfink M**. Cytotoxic natural antibodies against human tumours: an option for anti-cancer immunotherapy? *Autoimmun Rev*. 2008;7(6):491-495.
69. Rossmann E, Kraiczy P, Herzberger P, Skerka C, **Kirschfink M**, Simon MM, Zipfel PF, Wallich. BhCRASP-1 of the relapsing fever spirochete *Borrelia hermsii* is a factor H-and plasminogen-binding protein. *Int J Med Microbiol* 2008 S1, 272-283
70. Li W, Lei P, Yu B, Wu S, Peng J, Zhao X, Zhu H, **Kirschfink M**, Shen G. Screening and identification of a novel target specific for hepatoma cell line HepG2 from the FLITr bacterial peptide library. *Acta Biochim Biophys Sin (Shanghai)*. 2008;40(5):443-451.
71. Habbig S, Mihatsch MJ, Heinen S, Beck B, Emmel M, Skerka C, **Kirschfink M**, Hoppe B, Zipfel PF, Licht C. C3 deposition glomerulopathy due to a functional Factor H defect . *Kidney Int*. 2008; 75(11):1230-1234.
72. Huwendiek, S, Kadmon M, Jünger J, **Kirschfink M**, Bosse HM, Resch F, Duelli R, Bardenheuer HJ, Sonntag HG, T. Steiner T. Umsetzung der deutschen Approbationsordnung 2002 im modularen Reformstudiengang Heidelberger Curriculum Medicinale (HeiCuMed). *Zeitschrift für Hochschulentwicklung ZFHE Jg.3 / Nr.3 (Sept. 2008), 17-27.*
73. Skelin S, Huwendiek S, Nikendei S., Dieter P, **Kirschfink M**, Hans-Martin Bosse H.M Der gute POL-Tutor – sein oder nicht sein: Lehrfilme für Tutoren. *Z. Evid. Fortbild. Qual. Gesundheitswesen (ZEFQ)* 102 (2008) 634–641
74. Odening KE, Laufs S; Fruehauf S, Li, W, Fishelson Z and **Kirschfink M**. Enhanced complement resistance in drugselected P-glycoprotein expressing multidrug resistant ovarian carcinoma cells. *Clin Exp Immunol* 2008;155(2):239-248.

75. Nürnberg J, Witzke O, Saez AO, Vester U, Baba HA, Kribben A, Zimmerhackl LB, Janecke AR, Nagel M, **Kirschfink M**. Eculizumab for atypical hemolytic-uremic syndrome. *New Engl J Medicine* 2009; 29;360(5):542-544.
76. Guerra-Junior G, Grumach A, Lemos-Marini S, **Kirschfink M**, Condino-Neto A, Araujo M, De Mello M. Complement 4 phenotypes and genotypes in Brazilian patients with classical 21-hydroxylase deficiency, *Clin Exp Immunol* 2009; 155(2):182-188.
77. Botto M, **Kirschfink M**, Macor P, Pickering MC, Würzner R, Tedesco F. Complement in human diseases: Lessons from complement deficiencies. *Mol Immunol*. 2009; 46(14):2774-2783.
78. Halme J, Sachse M, Vogel H, Giese T, Klar E, **Kirschfink M**. Primary human hepatocytes are protected against complement by multiple regulators *Mol Immunol*. 2009; 46:2284-2289.
79. Mache CJ, Acham-Roschitz B, Frémeaux-Bacchi V, **Kirschfink M**, Zipfel PF, Roedel S, Vester U, Ring E. Complement Inhibitor Eculizumab in Atypical Hemolytic Uremic Syndrome. *Clin J Am Soc Nephrol*. 2009, 4(8): 1312-1316.
80. Märten A, Büchler MW, Werft W, Wente MN, **Kirschfink M**, Schmidt J. Soluble iC3b as an Early Marker for Pancreatic Adenocarcinoma Is Superior to CA19.9 and Radiology.. *J Immunother*. 2010 , 33 (2), 219-224.
81. Zipplies JK; **Kirschfink M**, Amann B, Hauck SM, Stangassinger M, Deeg CA. Complement factor B expression profile in a spontaneous uveitis model *Immunobiology* 2010; 215(12):949-955.
82. Bedarf J, Russ M, Ott S , Kecke T , **Kirschfink M**, Unger JK. Influence of acidemia and hypoxemia on CVVH haemocompatibility in a porcine model. *Nephrol Dialys Transpl* 2010 25(9):2960-2969.
83. Bosse HM, Huwendiek S, Skelin S, Kirschfink M, Nikendei C. Interactive film scenes for tutor training in problem-based learning (PBL): dealing with difficult situations. *BMC Med Educ*. 2010;10:52.
84. Emlen W, Li W, **Kirschfink M**. Therapeutic complement inhibition: New developments. *Semin Thromb Hemostasis* 2010; 36 (6): 660-668.
85. Geis N, Zell, Rutz R, Li W, Giese T, Schultz S, **Kirschfink M**. Inhibition of mCRP expression (CD46, CD55, CD59) by siRNA sensitizes tumor cells to complement attack. *CCDT* 2010; 10, 922-931.
86. Anna Christine Slagman, Christopher Bock, Hassan Abdel-Aty, Birgit Vogt, Frank, Gebauer, Gunnar Janelt, Franziska Wohlgemuth, Rene Morgenstern², Gülcan Yapici, Astrid Puppe, Diethelm Modersohn, Dörte Mans, Timo Jerichow, Sascha Ott, Rudolf Kunze, Wieland Schrödl, Christina Janko, Martin Hermann, Joachim, R. Kalden, Peter Kern, Hans Parsch, **Michael Kirschfink**, Jeanette Schulz-Menger, Rainer Röttgen, Juliane K. Unger, Ulrich Frei, Ralf Schindler, Martin Möckel, Ahmed Sheriff. Specific removal of C-reactive protein by apheresis in a porcine cardiac infarction model. *Blood purification* 2011;31:9-17.

87. Lapeyraque AL, Malina M, Fremeaux-Bacchi V, Boppel T, **Kirschfink M**, Oualha M, Proulx F, Clermont MJ, Le Deist F, Niaudet P, Schaefer F. Eculizumab in severe Shiga-toxin-associated HUS. *N Engl J Med*. 2011 Jun 30;364(26):2561-2563.
88. Chen Q, Müller D, Rudolph B, Hartmann A, Kuwertz-Bröking E, Wu K, **Kirschfink M**, Skerka C, Peter F, Zipfel PF. Combined C3b and Factor B Autoantibodies and MPGN Type 2. *New Engl J Med* 2011; 365(24):2340-2342.
89. Cinci M, **Kirschfink M**, Lorenz HM, Blank N. Remitting fever of unknown origin in a 20 year old male. *Arthritis Care & Res* 2012;64 (3), 459-464.
90. de Vries E; in collaboration with European Society for Immunodeficiencies (ESID) members. Patient-centred screening for primary immunodeficiency, a multi-stage diagnostic protocol designed for non-immunologists: 2011 update. *Clin Exp Immunol*. 2012;167(1):108-19.
91. Radhakrishnan S, Lunn A, **Kirschfink M**, Thorner PS, Hebert D, Langlois V, Pluthero FG, Licht C. Eculizumab and Refractory Membranoproliferative Glomerulonephritis. *N Engl J Med*. 2012;366(12):1165-6.
92. M. Kadmon, J. Jünger, T. Steiner, S. Huwendiek, **M. Kirschfink**, R. Duelli, C. Harter, S. Titz, R. Nawrotzki, F. Resch, H.G. Sonntag, C. Bartram. Das Reformcurriculum Heidelberger Curriculum Medicinale. Konzepte, Erreichtes, Ausblicke. In: Krukemeyer : Aus-und Weiterbildung in der klinische Medizin. Schattauer 2012.
93. Liu L, Li W, Li Z, **Kirschfink M**. Sublytic complement protects prostate cancer cells from tumour necrosis factor- α -induced cell death. *Clin Exp Immunol*. 2012;169(2):100-108.
94. Wang H, Vinnikov I, Shahzad K, Bock F, Ranjan S, Wolter J, Kashif M, Oh J, Bierhaus A, Nawroth P, **Kirschfink M**, Conway EM, Madhusudhan T, Isermann B. The lectin-like domain of thrombomodulin ameliorates diabetic glomerulopathy via complement inhibition. *Thromb Haemost*. 2012;108(6).
95. Tudoran R & **Kirschfink M**. Moderne Komplementanalytik: Indikationen-Methodik-Perspektiven. *J Lab Med* 2012; 36 (3): 125-134.
96. Chmilewsky F, Jeanneau C, Laurent P, **Kirschfink M**, About I. Pulp progenitor cell recruitment is selectively guided by a C5a gradient. *J Dent Res*. 2013;92(6):532-9.
97. Mamidi S, Cinci M, Hasmann M, Fehring V, **Kirschfink M**. Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab. *Mol Oncol*. 2013;7(3):580-94.
98. Bergseth G, Ludviksen JK, **Kirschfink M**, Giclas PC, Nilsson B, Mollnes TE. An international serum standard for application in assays to detect human complement activation products. *Mol Immunol*. 2013;56(3):232-9.
99. Noone D, Waters A, Pluthero FG, Geary DF, **Kirschfink M**, Zipfel PF, Licht C. Successful treatment of DEAP-HUS with eculizumab. *Pediatr Nephrol*. 2014;29(5):841-51.

100. Vasel M, Rutz R, Bersch C, Feick P, Singer MV, Kirschfink M, Nackchbandi IA. Complement activation correlates with liver Necrosis and Fibrosis in chronic hepatitis C. *Clin Immunol.* 2013 Dec 5;150(2):149-156.
101. Chen Q, Wiesener M, Eberhardt HU, Hartmann, A, Uzonyi, B, Kirschfink M, Amann K, Buettner M, Goodship T, Hugo C, Skerka C, Zipfel PF. Complement factor H-related hybrid protein deregulates complement in dense deposit disease. *J Clin Invest.* 2014 Jan 2;124(1):145-55.
102. Grumach AS, Ceccon ME, Rutz R, Fertig A, Kirschfink M. Complement profile in neonates of different gestational ages. *Scand J Immunol.* 2014 2014Apr;79(4):276-81.
103. Roos M, Kadmon M, Kirschfink M, Koch E, Jünger J, Strittmatter-Haubold V, Steiner T. Developing medical educators--a mixed method evaluation of a teaching education program. *Med Educ Online.* 2014 Mar 27;19:23868.
104. Eggert-Kruse W, Scholz S, Kirschfink M, Strowitzki T. Recurrent miscarriages, innate immunity, and autoimmune reaction to chlamydial 60-kDa heat shock protein-is there an association? *Fertil Steril.* 2014 Jun;101(6):1675-1680.
105. Wehling C, Kirschfink M. Tailored eculizumab regimen for patients with atypical hemolytic uremic syndrome: requirement for comprehensive complement analysis. *J Thromb Haemost.* 2014 12(9):1437-1439.
106. Grumach AS, Kirschfink M. Are complement deficiencies really rare? Overview on prevalence, clinical importance and modern diagnostic approach. *Mol Immunol.* 2014;61(2):110-117.
107. Cinci M, Mamidi S, Li W, Fehring V, Kirschfink M. Targeted delivery of siRNA using transferrin-coupled lipoplexes specifically sensitizes CD71 high expressing malignant cells to antibody-mediated complement attack. *Target Oncol.* 2015; 10:405-4013
108. Hayes W, Tschumi S, Ling SC, Feber J, Kirschfink M, Licht C. Eculizumab hepatotoxicity in pediatric aHUS. *Pediatr Nephrol.* 2015;30(5):775-81.
109. Kronbichler A, Frank R, Kirschfink M, Szilágyi A, Csuka D, Prohászka Z, Schratzberger P, Lhotta K, Mayer G. Efficacy of eculizumab in a patient with immunoadsorption-dependent catastrophic antiphospholipid syndrome: a case report. *Medicine (Baltimore).* 2014;93(26):e143.
110. Mamidi S, Höne S, Teufel C, Sellner L, Zenz T, Kirschfink M. Neutralization of membrane complement regulators improves complement-dependent effector functions of therapeutic anticancer antibodies targeting leukemic cells. *Oncoimmunology.* 2015; 22;4(3):e979688.
111. Filippidis FT, Schwartz SM, Becker N, Dyckhoff G, Kirschfink M, Dietz A, Becher H, Ramroth H. Association of history of allergies and influenza-like infections with laryngeal cancer in a case-control study *European Archives of Oto-Rhino-Laryngology and Head & Neck.* 2015 Aug;272(8):2063-9

112. Schalk G, Kirschfink M, Wehling C, Gastoldi S, Bergmann C, Hoppe B, Weber LT. A complicated case of atypical hemolytic uremic syndrome with frequent relapses under eculizumab. *Pediatr Nephrol.* 2015 30(6):1039-42.
113. Hohenstein B, Licht C, Wiesener M, Amann K, Schaefer F, Serka C, Bergmann C, Kirschfink M, Zipfel P, Hugo C. „State-of-the art“: C3-Glomerulopathie und membranoproliferative Glomerulonephritis. *Der Nephrologe* 2015;10:327-340
114. Kraft S, Klemis V, Sens C, Lenhard T, Jacobi C, Samstag Y, Wabnitz G, Kirschfink M, Wallich R, Hänsch GM, Nakchbandi IA. Identification and characterization of a unique role for EDB fibronectin in phagocytosis. *Mol Med (Berl).* 2016 94(5):567-581.
115. Devarapu SK, Mamidi S, Plöger F, Dill O, Blixt O, Kirschfink M, Schwartz-Albiez R. Cytotoxic Activity Against Human Neuroblastoma and Melanoma Cells Mediated by IgM Antibodies Derived from Peripheral Blood of Healthy Donors. *Int J Cancer.* 2016 ; 138(12): 2963-7293.
116. Ahlenstiel-Grunow T, Hachmeister S, Bange FC, Wehling C, Kirschfink M, Bergmann C, Pape L. Systemic complement activation and complement gene analysis in enterohaemorrhagic *Escherichia coli*-associated paediatric haemolytic uraemic syndrome. *Nephrol Dial Transplant.* 2016 Jul;31(7):1114-1121.
117. Prohászka Z, Nilsson B, Frazer-Abel A, Kirschfink M. Complement analysis 2016: Clinical indications, laboratory diagnostics and quality control. *Immunobiology.* 2016; 221(11):1247-58.
118. Słabicki M, Lee KS, Jethwa A, Sellner L, Sacco F, Walther T, Hülleln J, Dietrich S, Wu B, Lipka DB, Oakes CC, Mamidi S, Pyrzyńska B, Winiarska M, Oleś M, Seifert M, Plass C, Kirschfink M, Boettcher M, Gołąb J, Huber W, Fröhling S, Zenz T. Dissection of CD20 regulation in lymphoma using RNAi. *Leukemia.* 2016;30(12):2409-2412.
119. Mamidi S, Höne S, Kirschfink M. The complement system in cancer: Ambivalence between tumour destruction and promotion. *Immunobiology.* 2017;222(1):45-54.
120. Wehling C, Amon O, Bommer M, Hoppe B, Kentouche K, Schalk G, Weimer R, Wiesener M, Hohenstein B, Tönshoff B, Büscher R, Fehrenbach H, Gök ÖN, Kirschfink M. Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders. *Clin Exp Immunol.* 2017;187(2):304-315.
121. Schick T, Steinhauer M, Aslanidis A, Altay L, Karlstetter M, Langmann T, Kirschfink M, Fauser S. Local complement activation in aqueous humor in patients with age-related macular degeneration. *Eye (Lond).* 2017;31(5):810-813.
122. Hackl A, Ehren R, Kirschfink M, Zipfel PF, Beck BB, Weber LT, Habbig S. Successful discontinuation of eculizumab under immunosuppressive therapy in DEAP-HUS. *Pediatr Nephrol.* 2017;32(6):1081-1087.
123. Röttgerding F, Wagemakers A, Koetsveld J, Fingerle V, **Kirschfink M**, Hovius JW, Zipfel PF, Wallich R, Kraiczy P. Immune evasion of *Borrelia miyamotoi*: CbiA, a novel outer surface protein exhibiting complement binding and inactivating properties. *Sci Rep.* 2017 Mar 22;7(1):303.

124. Riedemann NC, Habel M, Ziereisen J, Hermann M, Schneider C, Wehling C, **Kirschfink M**, Kentouche K, Guo R. Controlling the anaphylatoxin C5a in diseases requires a specifically targeted inhibition. *Clin Immunol.* 2017;180:25-32.

125. Münch J, Bachmann A, Grohmann M, Mayer C, **Kirschfink M**, Lindner TH, Bergmann C, Halbritter J. Effective immunosuppressive management with belatacept and eculizumab in post-transplant aHUS due to a homozygous deletion of *CFHR1/CFHR3* and the presence of CFH antibodies. *Clin Kidney J.* 2017 Dec;10(6):742-746.

126. Gallenkamp J, Spanier G, Wörle E, Englbrecht M, **Kirschfink M**, Greslechner R, Braun R, Schäfer N, Bauer RJ, Pauly D. A novel multiplex detection array revealed systemic complement activation in oral squamous cell carcinoma. *Oncotarget.* 2017 Dec 6;9(3):3001-3013